The development stage of entrepreneurial expansion (2005 - 2009)

     In 2005, Dr. Xue Jijun, Dr. Gao Qiang and Dr. Zheng Baofu of University of Hong Kong plan and prepare the project. From 2005 to 2009, it took 4 years to complete the stage of individual entrepreneurship. In this process, the company has expanded its business model from R & D + sales + technology to more than 20 R & D teams. The organizational system also evolved from "small boat structure" to "fleet structure".

The stage of industrial sustainable development (2009 - 2010)

      In 2009, with the approval of the people's Government of Gansu Province, it was officially registered as "Gansu Hao Tian medical science and technology limited liability company" with "technical service to drive product sales", exploring the road of high and new industry development, and relying on the Silver Industrial Technology Research Institute of Lanzhou University to establish long-term and stable production and learning with Lanzhou University. Research cooperation relations. To promote the rapid expansion of the scale of operation of the company, the organizational system is also adjusted from "fleet structure" to "big ship structure". At the same time, we should take an active part in national reform and reintegrate enterprise culture and resources through integrating new technologies and capital and introducing talents. At this stage, the company has formed the main industry of technological research and development, technical consulting, technology transfer and technical service, which are the main industry of innovation medicine technology research and development, technical consultation, technology transfer and technical service. The core of the value concept is "love in the heart", and the enterprise management model and performance increase at an annual rate of more than 50%. Long; the company has won many awards during its development and growth, and has been awarded the honorary title of "high-tech enterprise recognition".

The stage of intensive brand development (2010 - 2016)

      Continuous concept innovation, mechanism innovation and technological innovation have injected the inherent motive force for the development of the enterprise, made the enterprise realize the leapfrog development, and completed the declaration of more than 20 patents successively. At present, there are ten patents authorized. It has been fully affirmed by the leaders of the high-tech zones and the authority of the industry. This also shows that the products of the company have good social image and wide market recognition. In 2017, the company's business model was adjusted to "technology + service". With the production and sale of pharmaceutical intermediates as the main starting materials, the registration of raw materials for registration is starting, and gradually become the raw material drug production enterprises, and finally will be transformed into pharmaceutical enterprises. From the development and production of generic drugs, it has gradually become an innovative pharmaceutical research and development enterprise. At the same time, the company maintains cooperation with four new drug development enterprises through the work with Qilu pharmaceutical, Sichuan colen, Yangzi River Pharmaceutical Industry and other domestic pharmaceutical enterprises, to assist the other party to make customized synthesis and production of new molecules in the development of innovative drugs, and lay a solid foundation for the public market to expand the market. At this stage, the Hao Tian people put forward the vision of "building the best pharmaceutical factory in Gansu and being the first class new drug".

The stage of leaping and harmonious development (2016 - 2018)

     In 2016, Hao Tian put forward the development strategy of "developing new medicines with his own technology". Facing the stock market reform and listing, the project transfer and so on, Hao Tian has set up a new development plan, on the internal adjustment management structure, relying on the platform, and establishing the pharmaceutical intermediates industry alliance. In 2016, with the advantage of innovative technology, we won the two prize of the two China Innovation and Entrepreneurship Competition (Gansu competition area) in succession. In the same year, the company, in order to integrate resources, expand the scale, better support and serve the development of the domestic pharmaceutical industry, formed a large-scale, systematic production, set up 100 mu of raw material production base in Yinxi, and broke ground in May 2016. In March 2017, the construction of the base was based on the standardization of petrochemical and the requirements of the FDA drug production. In March 2018, the equipment and equipment entered the factory, and the base adopted the new technology and new equipment such as the integrated public engineering, the semi-automatic production control system and the micro channel. It is bound to become the first-class and global chemical raw material base. And it is planned to be put into operation in October 2018.

Building competitive pharmaceutical enterprises (2018 to now)

       The company adheres to the strategic guidance, attaches great importance to the technology research and development of the products, pays attention to the construction of the team, based on the new era and faces new opportunities, puts forward the thought of socialism with Chinese characteristics in the new era of Xi Jinping as the guide, and takes the nineteen spirit as the main line to learn and carry out the spirit of the new era, to strengthen the construction of the party in an all-round way. This goal is to adhere to the four drive linkage, achieve high quality development, be a leading leader in the Gansu pharmaceutical industry, a resource integrant, and make the best new medicine in Gansu, and become a competitive pharmaceutical enterprise in the industry.